Portfolio News
Sofinnova Industrial Biotech
Novameat launches Balanced Protein ingredient for meat makers
Related Company
NovameatRelated Strategy
Industrial BiotechBARCELONA, 9th March 2026 — As global beef prices reach historic highs and regulatory pressure on sustainability intensifies, Novameat is positioning its technology as a vital strategic asset for the meat processing industry. Today, the company launches its "Balanced Protein" framework—a high-performance texturised protein solution designed to enable manufacturers hedge against market volatility while meeting the urgent demand for lower-carbon, highly-nutritious products.
In an era where traditional animal protein faces increasing supply chain instability, Novameat’s texturised ingredients allow processors to "optimise the plate". By integrating Novameat’s plant-based structures into traditional meat processing lines, manufacturers can significantly reduce production costs while significantly enhancing the final product’s juiciness and texture.
"The industry is currently navigating a fundamental shift in how protein is sourced and valued," says Dr. Giuseppe Scionti, CEO and founder of Novameat. "Our technology was developed to do more than just lower costs; it’s about adding functional value. By introducing plant-derived fibre—a nutrient naturally absent in animal meat—we are helping our partners lead the 2026 gut-health movement. Crucially, these ingredients also allow for a significant increase in total protein content and a decrease in saturated fats, sugars and salt, delivering a more nutrient-dense product that satisfies both the athlete and the health-conscious consumer without sacrificing the sensory experience."
Already active in five European markets, Novameat’s ingredients are engineered for seamless "plug-and-play" integration. Beyond the economic benefits, the strategy offers a major environmental upgrade, with the plant-based components carrying a carbon footprint up to 99% lower than conventional beef. This enables manufacturers to hit aggressive ESG targets.
The efficacy of the "Balanced Protein" approach was recently validated in blind panel tests by world-class flavour experts and Michelin-starred chefs, where a Novameat-enhanced burger outperformed Spain’s top-selling 100% beef burger.
Related News
Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances
Partnership with French cancer research network FFCD expands Bioptimus’s STELA programme
Moon Surgical and Uncovr Announce First 20 Clinical Cases of Automated Operative Reporting on Maestro®
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board
TISSIUM secures €60 million to support commercial and clinical activities and platform expansion